BioMarin EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit

BioMarin Pharmaceutical (NASDAQ:BMRN): Q2 GAAP EPS of -$0.16 misses by $0.04.

Revenue of $429.5M (+10.8% Y/Y) beats by $12.1M.

For the FY20, BioMarin continues to expect to be profitable on a GAAP basis for the first time.

Press Release

https://seekingalpha.com/news/3600256-biomarin-pharmaceutical-eps-misses-0_04-beats-on-revenue-expects-fy20-gaap-profit